ALZNAlzamend Neuro Inc
$1.16
$0.01
(0.87%)
Closed $1.16
$0.00
(0.00%)
After Hours
Reported EarningsSep 16
Mkt Cap$4.38M
Vol41,641.00
Fundamentals
Mkt Cap
$4.38M
Volume
-
52W High
$3.60
52W Low
$0.84
PE Ratio
-0.26
Avg. Volume
62,885.61
EPS (Annual)
-$11.32
Rev/Employee
$0.00
Earnings
Sep 16
Insider Buying: Alzamend Neuro (NASDAQ:ALZN) Director Buys 108,388 Shares of Stock
Alzamend Neuro, Inc. (NASDAQ:ALZN - Get Free Report) Director Milton Ault III bought 108,388 shares of the stock in a transaction dated Tuesday, April 14th. The shares were purchased at an average price of $1.00 per share, for a total transaction of $108,388.00. Following the purchase, the director...
MarketBeat
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 'Lithium in Brain' Study in a Trial Conducted at Massachusetts General Hospital Alzamend Neuro Reports...
PR Newswire
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001...
PR Newswire
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 'Lithium in Brain' Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital Alzamend Neuro Initiates...
PR Newswire
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Here is how Allogene Therapeutics (ALLO) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.
Zacks
Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year?
Here is how AIM ImmunoTech Inc. (AIM) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.
Zacks
EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?
Embecta's Q4 earnings loom as product momentum, global trends and recent strategic gains set the stage for potential top-line support.
Zacks
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 'Lithium in Brain' Study Conducted at Massachusetts General Hospital Alzamend Neuro Announces Completion of...
PR Newswire
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants
Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for better brain delivery and safety, reducing the need for drug monitoring.read more...
Benzinga
<
1
2
...
>
Advertisement|Remove ads.
Latest ALZN News
ViewInsider Buying: Alzamend Neuro (NASDAQ:ALZN) Director Buys 108,388 Shares of Stock
MarketBeat
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
PR Newswire
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
PR Newswire
Advertisement|Remove ads.